(Q35710147)

9 August 2017

1 reference

title

Active and passive immunization against Clostridium difficile diarrhea and colitis (English)

1 reference

9 August 2017

0 references

Clostridium difficile

0 references

0 references

1 reference

Paul J Giannasca

1

1 reference

9 August 2017

Michel Warny

series ordinal

2

1 reference

9 August 2017

language of work or name

English

0 references

publication date

1 February 2004

1 reference

9 August 2017

number of pages

9

1 reference

inferred from page(s)

published in

Vaccine

1 reference

9 August 2017

volume

22

1 reference

9 August 2017

issue

7

1 reference

9 August 2017

page(s)

848-856

1 reference

Clostridium difficile colitis

9 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.030

Nosocomial acquisition of Clostridium difficile infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.030

Health care costs and mortality associated with nosocomial diarrhea due to Clostridium difficile

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.030

Epidemiology of Clostridium difficile in infants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.030

Epidemiology of antibiotic-associated colitis; isolation of Clostridium difficile from the hospital environment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.030

Isolation of Clostridium difficile from the environment and contacts of patients with antibiotic-associated colitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.030

Clostridium difficile colonization and diarrhea at a tertiary care hospital

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.030

Prospective randomised trial of metronidazole versus vancomycin for Clostridium-difficile-associated diarrhoea and colitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.030

A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.030

Recurrence of symptoms in Clostridium difficile infection--relapse or reinfection?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.030

Role of FliC and FliD flagellar proteins of Clostridium difficile in adherence and gut colonization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.030

Binding of Clostridium difficile surface layer proteins to gastrointestinal tissues

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.030

Characterization of a cell surface protein of Clostridium difficile with adhesive properties

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.030

Large clostridial cytotoxins--a family of glycosyltransferases modifying small GTP-binding proteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.030

pH-induced conformational changes in Clostridium difficile toxin B

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.030

Low pH-induced formation of ion channels by clostridium difficile toxin B in target cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.030

Glucosylation of Rho proteins by Clostridium difficile toxin B.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.030

The enterotoxin from Clostridium difficile (ToxA) monoglucosylates the Rho proteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.030

GT160-246, a toxin binding polymer for treatment of Clostridium difficile colitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.030

A novel cytotoxin from Clostridium difficile serogroup F is a functional hybrid between two other large clostridial cytotoxins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.030

Fatal pseudomembranous colitis associated with a variant clostridium difficile strain not detected by toxin A immunoassay

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.030

Clostridium difficile toxin B is more potent than toxin A in damaging human colonic epithelium in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.030

Clostridium difficile toxin B is an inflammatory enterotoxin in human intestine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.030

Bovine milk antibodies for health

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.030

Anti-Clostridium difficile bovine immunoglobulin concentrate inhibits cytotoxicity and enterotoxicity of C. difficile toxins.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.030

Hepatobiliary transport of plasma IgA in the mouse: contribution to clearance of intravascular IgA

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.030

Hepatobiliary transport of IgA in the golden Syrian hamster (Mesocricetus auratus)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.030

Clostridium difficile toxin B disrupts the barrier function of T84 monolayers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.030

Clostridium difficile toxin A perturbs cytoskeletal structure and tight junction permeability of cultured human intestinal epithelial monolayers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.030

Serum antibody response to toxins A and B of Clostridium difficile

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.030

Clostridium difficile infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.030

Treatment with intravenously administered gamma globulin of chronic relapsing colitis induced by Clostridium difficile toxin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.030

Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.030

Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.030

Safety and immunogenicity of increasing doses of a Clostridium difficile toxoid vaccine administered to healthy adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.030

Clostridium difficile vaccine and serum immunoglobulin G antibody response to toxin A

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.030

Intravenous immunoglobulin for recurrent Clostridium difficile diarrhoea

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.030

Intravenous immunoglobulin therapy for severe Clostridium difficile colitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.030

Gamma globulin administration in relapsing Clostridium difficile-induced pseudomembranous colitis with a defective antibody response to toxin A

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.030

Survival of anti-Clostridium difficile bovine immunoglobulin concentrate in the human gastrointestinal tract.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.030

Morphological changes in adherent cells induced by Clostridium difficile toxins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.030

7 January 2021

Toxin A of Clostridium difficile is a potent cytotoxin

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.030

7 January 2021

Biological activities of toxins A and B of Clostridium difficile

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.030

7 January 2021

Characterization of a toxin A-negative, toxin B-positive strain of Clostridium difficile responsible for a nosocomial outbreak of Clostridium difficile-associated diarrhea.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.030

7 January 2021

Immunization of adult hamsters against Clostridium difficile-associated ileocecitis and transfer of protection to infant hamsters

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.030

7 January 2021

Effects of the two toxins of Clostridium difficile in antibiotic-associated cecitis in hamsters.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.030

7 January 2021

Characterization of toxins A and B of Clostridium difficile with monoclonal antibodies

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.030

7 January 2021

Human colonic aspirates containing immunoglobulin A antibody to Clostridium difficile toxin A inhibit toxin A-receptor binding

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.030

7 January 2021

Human antibody response to Clostridium difficile toxin A in relation to clinical course of infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.030

7 January 2021

10.1016/J.VACCINE.2003.11.030

Identifiers

DOI

1 reference

9 August 2017

1 reference